We are live on ! Find out more
GTC

Ghost Tree Capital Portfolio holdings

AUM $331M
1-Year Est. Return 70.11%
This Fund
S&P 500
This Quarter Est. Return
+29.13%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$244M
AUM Growth
+$22M
Cap. Flow
-$10.5M
Cap. Flow %
-4.28%
Top 10 Hldgs %
43.92%
Holding
93
New
19
Increased
15
Reduced
7
Closed
46

Top Buys

1
WMGI
Wright Medical Group Inc
WMGI
+$10.8M
2
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$9.94M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$9.37M
4
BLUE
bluebird bio
BLUE
+$9.25M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$8.83M

Top Sells

1
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$13.4M
2
AGN
Allergan plc
AGN
+$10.2M
3
GILD icon
Gilead Sciences
GILD
+$6.87M
4
CELG
Celgene Corp
CELG
+$6.49M
5
AVDL
Avadel Pharmaceuticals
AVDL
+$5.71M

Sector Composition

1 Healthcare 89.59%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TNDM icon
26
Tandem Diabetes Care
TNDM
$1.17B
$4.13M 1.69%
+35,000
New +$3.47M
SRPT icon
27
Sarepta Therapeutics
SRPT
$1.82B
$3.86M 1.58%
100,000
+90,000
+900% +$2.92M
TVTX icon
28
Travere Therapeutics
TVTX
$5.27B
$3.86M 1.58%
+200,000
New +$4M
SGYP
29
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
$3.4M 1.39%
600,000
– –
GNMK
30
DELISTED
GenMark Diagnostics, Inc
GNMK
$3.18M 1.3%
410,000
-115,000
-22% -$883K
ARCT icon
31
Arcturus Therapeutics
ARCT
$172M
$3.14M 1.29%
71,429
-26,994
-27% -$1.22M
TNXP icon
32
Tonix Pharmaceuticals
TNXP
$198M
– –
0
– –
ADAP
33
DELISTED
Adaptimmune Therapeutics
ADAP
$2.53M 1.04%
+210,000
New +$2.06M
ENTL
34
DELISTED
Entellus Medical, Inc. Common Stock
ENTL
$2.53M 1.04%
+150,000
New +$2.55M
VCYT icon
35
Veracyte
VCYT
$4.72B
$2.52M 1.03%
350,000
+147,200
+73% +$991K
CYNA
36
DELISTED
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
$2.32M 0.95%
151,630
-23,370
-13% -$355K
PCRX icon
37
Pacira BioSciences
PCRX
$1.01B
$2.3M 0.94%
30,000
-50,000
-63% -$2.83M
CLVS
38
CALL
DELISTED
Clovis Oncology, Inc.
CLVS
$1.75M 0.72%
+50,000
New +$3.22M
LAB icon
39
Standard BioTools
LAB
$350M
$1.62M 0.66%
+150,000
New +$1.47M
DVAX
40
DELISTED
Dynavax Technologies
DVAX
$1.33M 0.54%
55,000
-110,000
-67% -$2.76M
CORI
41
DELISTED
Corium International, Inc.
CORI
$1.01M 0.42%
125,000
– –
RGNX icon
42
Regenxbio
RGNX
$511M
$996K 0.41%
60,000
– –
FOLD
43
CALL
DELISTED
Amicus Therapeutics
FOLD
$970K 0.4%
+100,000
New +$901K
CPRX icon
44
Catalyst Pharmaceutical
CPRX
$921K 0.38%
376,000
+26,000
+7% +$74.5K
AKTX
45
Akari Therapeutics
AKTX
$19.3M
$683K 0.28%
59
+34
+136% +$505K
SBBP
46
DELISTED
Strongbridge Biopharma plc.
SBBP
$553K 0.23%
+72,726
New +$523K
OCRX
47
DELISTED
Ocera Therapeutics, Inc.
OCRX
$390K 0.16%
125,000
– –
ACHC icon
48
Acadia Healthcare
ACHC
$3.17B
– –
-40,000
Closed -$1.32M
ALNY icon
49
CALL
Alnylam Pharmaceuticals
ALNY
$35.7B
– –
-75,000
Closed -$6.03M
ASND icon
50
Ascendis Pharma A/S
ASND
$17.1B
– –
-97,135
Closed -$1.72M
1
2
3 4

Similar funds

SF
Susquehanna Foundation Bala Cynwyd, Pennsylvania $333M AUM 35.73% 1-Year Est. Return
AFS
Annapolis Financial Services Annapolis, Maryland $338M AUM 23.49% 1-Year Est. Return
SFA
Source Financial Advisors New York $338M AUM 33.62% 1-Year Est. Return
E
ETFidea Syracuse, New York $316M AUM 29.57% 1-Year Est. Return
OHCM
Oak Hill Capital Management New York $310M AUM 17.23% 1-Year Est. Return
MC
Minot Capital Broomfield, Colorado $353M AUM 25.25% 1-Year Est. Return
BRA
Biechele Royce Advisors Fishers, Indiana $303M AUM 20.64% 1-Year Est. Return
S
Syntrinsic Denver, Colorado $301M AUM 27.27% 1-Year Est. Return

Ghost Tree Capital's Q4 2015 Portfolio in Review

As of Q4 2015, Ghost Tree Capital held 93 positions worth $244M, up 9.9% from $222M the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Ghost Tree Capital withdrew a net $10.5M in Q4 2015, closing 46 positions and reducing 7 holdings. Its most notable exit was Allergan plc, an estimated $10.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 83% a quarter earlier.

Against the trend, Ghost Tree Capital opened a new position in Wright Medical Group Inc worth $12.1M.

  • Ghost Tree Capital's largest Q4 2015 buy was Wright Medical Group Inc: 500,000 shares worth $12.1M.
  • Ghost Tree Capital added most to Portola Pharmaceuticals, Inc. in Q4 2015, an estimated $9.94M increase.
  • Ghost Tree Capital's biggest Q4 2015 reduction was Five Prime Therapeutics, Inc., cutting an estimated $13.4M.
  • Ghost Tree Capital fully exited Allergan plc in Q4 2015, selling an estimated $10.2M.
  • Ghost Tree Capital's ten largest holdings make up 44% of its $244M portfolio in Q4 2015.
  • Ghost Tree Capital opened 19 new positions and closed 46 in Q4 2015.
  • Ghost Tree Capital's portfolio value rose 9.9% quarter-over-quarter to $244M.

Based on Ghost Tree Capital's 13F filing for Q4 2015, filed 16 Feb 2016.